Literature DB >> 26406949

MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression.

Juanjuan Bai, Zhongling Zhang, Xing Li, Huifan Liu.   

Abstract

OBJECTIVE: The role of miR-365 in cancer cells seemed controversial in previous studies. We thereby in this article aimed to define the role of miR-365 in malignant melanoma (MM) pathogenesis.
METHODS: We detected miR-365 expression in malignant melanoma cell lines and then investigated the effects of miR-365 on the metastasis and malignancy of melanoma cells. The correlation between miR-365 level and NRP1 (neuropilin1) was further investigated in clinical malignant melanoma specimens.
RESULTS: MiR-365 was strongly down-regulated in malignant melanoma (MM) tissues and cell lines, and its expression levels were associated with lymph node metastasis and clinical stage, as well as overall survival and replase-free survival of MM. We also found that ectopic expression of miR-365 inhibited MM cell proliferation and MM metastasis in vitro and in vivo. We further identified a novel mechanism of miR-365 to suppress MM growth and metastasis. NRP1 was proved to be a direct target of miR-365, using luciferase assay and western blot. NRP1 over-expression in miR-365 expressing cells could rescue invasion and growth defects of miR-365. In addition, miR-365 expression inversely correlated with NRP1 protein levels in MM.
CONCLUSION: Our data suggest that miR-365 functions as a tumor suppressor in MM development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for MM.

Entities:  

Keywords:  Malignant melanoma (MM); cancer biomarker; invasion and metastasis; miR-365; neuropilin1 (NRP1); pathogenesis; target therapy

Mesh:

Substances:

Year:  2015        PMID: 26406949     DOI: 10.3233/CBM-150500

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  13 in total

Review 1.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

2.  MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.

Authors:  Yanli Wang; Chunling Xu; Yun Wang; Xiaomeng Zhang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 3.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 4.  Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Authors:  Hildegard Kehrer-Sawatzki; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2017-02-17       Impact factor: 4.132

5.  MicroRNA-365 targets multiple oncogenes to inhibit proliferation, invasion, and self-renewal of aggressive endometrial cancer cells.

Authors:  Chunfang Wang; Ke Su; Yanyan Zhang; Weiwei Zhang; Danxia Chu; Qian Zhao; Ruixia Guo
Journal:  Cancer Manag Res       Date:  2018-10-30       Impact factor: 3.989

6.  Exosomes impact survival to radiation exposure in cell line models of nervous system cancer.

Authors:  Oliver D Mrowczynski; Achuthamangalam B Madhankumar; Jeffrey M Sundstrom; Yuanjun Zhao; Yuka Imamura Kawasawa; Becky Slagle-Webb; Christine Mau; Russell A Payne; Elias B Rizk; Brad E Zacharia; James R Connor
Journal:  Oncotarget       Date:  2018-11-16

7.  FOXK1, Regulated by miR-365-3p, Promotes Cell Growth and EMT Indicates Unfavorable Prognosis in Breast Cancer.

Authors:  Fucun Gao; Juan Tian
Journal:  Onco Targets Ther       Date:  2020-01-21       Impact factor: 4.147

8.  Shift of EMT gradient in 3D spheroid MSCs for activation of mesenchymal niche function.

Authors:  Sohee Jeon; Ho-Sun Lee; Ga-Young Lee; Gyeongsin Park; Tae-Min Kim; Jihye Shin; Cheolju Lee; Il-Hoan Oh
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

9.  RAB22A overexpression promotes the tumor growth of melanoma.

Authors:  Feng Su; Yifei Chen; Shilin Zhu; Fangfang Li; Shuang Zhao; Lisa Wu; Xiang Chen; Juan Su
Journal:  Oncotarget       Date:  2016-11-01

10.  Analysis of the expression levels and clinical value of miR-365 and miR-25 in serum of patients with non-small cell lung cancer.

Authors:  Dongxuan Huang; Wenfang Ou; Huifen Tong; Ming Peng; Yamei Ou; Zeqing Song
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.